A prospective, randomized placebo-controlled multicenter trial evaluating fenoldopam mesylate for the prevention of contrast induced nephropathy: The CONTRAST trial  by Stone, Gregg W. et al.
JACC March 19,2003 ABSTRACTS - Angiography & Interventional Cardiology 83A 
11:30 a.m. 
879-5 Beta Radiation With Direct Stenting: Final Results of the 
BRIDGE Trial 
Patrick W. Serruvs, Willlam Wijns, Ivan de Scheerder, Paul A. van den Heuvel, Wolfgang 
Rutsch. Helmut D. Gloaar. Carlos Macava. Pierre H. Materne. Heike Vonhausen. Patricia 
I  
C. Otto-Terlouw, Erasmus Medical Center, Rotterdam, The Netherlands 
The BRIDGE study is a mulhcenter, randomized controlled clinical trial evaluating the 
acute and long-term efficacy of intravascular brachyiherapy (VET) with P-32 immediately 
following direct stenting (20 Gy 1 mm inside the coronary wall). 
VBT at the time of stem implantation for de nw0 lesions has not yielded good results and 
IS presently abandoned. We wanted to revisit this approach and have tried to optimize all 
procedural steps: ideal case selection, use of Ilb-llla blockers, direct stenting. awdance 
of edge damage, source centering, IVUS guided dosimetry and adequate radiation cov- 
erage. Patients were randomized to VBT or no-VBT. The sample size has at least 64% 
power to detect a 50% decrease I” loss of MLD as assessed by QCA at 6 months (pri- 
mary endpoint). The secondary endpornts are clinical and safety outcomes (I, 6 and 12 
mths), restenosis (50% diameter stenosis), remodelling and neo-intimal hyperplasia by 
IVUS, late thrombotic occlusion (up to 12 mths). Inclusion criteria: stable or unstable 
angina or documented silent ischemia with one or two successfully stented de nwo 
lesions at least 2.5-4.0 mm in diameter and up to ISmm long. Between Feb 2001 and 
Mar 2002, 112 patients (1.04 lesionslpt) were randomized to VBT or no-VBT at 8 sites in 
Europe. Of the VBT patients 93% were successfully treated. Baseline characteristics: 
age 60.5 yrs. male 79.8%, unstable 25.5%, stable angina 68.2%, silent ischemia 5.5%. 
Pre-procedure (N=81): mean vessel size was 2.84 vs. 2.65 mm, MLD was 0.95 vs. 1.05 
mm and lesson length was 10.9 vs. 11 .O mm (VBT vs. no-VBT). Post-procedure: mean 
vessel size was 2.63 vs. 2.82 mm and MLD was 1.78 vs. 2.04 mm. Stented segment: 
mean vessel size was 3.04 vs. 3.03 mm, MLD post was 2.69 vs. 2.67 mm, diameter 
stenosis was 11 vs. 12 % (VBT vs. no-VBT). Irradiated segment (defined by the length of 
the effective radiabon source, full dose prescribed): mean vessel size was 2.98 mm, MLD 
post was 2.05 mm, diameter stenosis was 32%. MACCE up to 30 days: death O%, Q-MI 
1.8%. non-Q-MI 2.7%, CABG 0%. re-PTCA 0.9% and 1.8% sub-acute occlusion. 
The final results, including 12 months follow-up, will be presented during the meeting. 
11:45 a.m. 
879-6 Sirolimus-Eluting Stent or lntracoronary Brachytherapy 
to Treat In-Stent Restenosis 
Fausto Feres. Juan S. Munoz, Alexandre A. Abizaid, Rodolfo Staico, Luiz A. Mattes, 
Gala Maldonado, Marinella Centernero. Luiz F. Tanajura, Aurea J. Chaves, lbraim Pinto, 
Andrea S. Abizaid, Amanda Sousa, Jose Eduardo M. Sousa, Institute Dante Pazzanese 
of Cardiology, Sao Paula, Brazil 
Background: lntracoronary Beta-Radiation Therapy (BT) has been shown to be effec- 
tive to treat in-stent restenosis (ISR) in large randomized clinical trials. Drug- eluting 
stems (DES) also have been successfully used to treat ISR in small pilot studies. The 
purpose of this study is to report clinical and angiographic outcomes of patients (Pts) with 
ISR treated either with balloon angioplasty followed by BT or DES. 
Methods: From March 2001 to April 2002, 50 consecutive pts with ISR were treated 
either with Sirolimus- eluting stent or BT (Novoste,Beta-Cath).The first 25 pts were 
treated with DES (one or two 18 mm Cypher stent were used per patient) and the second 
25 treated with BT (40 mm source). Angiographic quantifications were performed in all 
pts at baseline (Post) and the follow-up (FUP) (12 months for DES and 6 months for BT). 
Results: Clinical FUP was available at 12 months for all pts in DES group and for 22 
(88%) in the ??T group who completed 6 months FUP. 100% of DES group and 82% of 
the BT group were free of MACE (TVR, AMI or death)-p=0.04. Angiographic FUP was 
done in all DES group at 12 months and 86% of the pts in BT group (19/22). 
Angiographic Results(mm) DES(n=25) BT(n=19) 
In-lesion length 
Reference Diameter Post 
MLD Pre 
MLD in-segment Post 
MLD in-stent Post 
%DS Pre 
%DS In-segment Post 
%DS in-stem Post 
Acute gal” 
Reference Diameter FUP 
MLD in-segment FUP 
MLD in-stent FUP 
Late loss in-segment 
Late 10s in-stent 
Angiographic restenosls 
13.66e7.80 16.74e3.63 
2.8*0.36 2.70+0.35 
1.05+0.31 1.08+0.34 
2.35i0.37 1.98*0.30 
2.72+0.31 1.99*0.31’ 
62.06i10.71 63.5li8.90 
16.13+8.14 28.54e7.94’ 
2.56k9.21 29.73+8.28’ 
1.67eO.34 0.91*0.43’ 
2.78+0.34 2.6220.33 
2.19*0.56 1.49*0.24 
2.36eO.57 1.90*0.31’ 
0.16iO.42 0.49*0.13 
0.35io.45 0.10*0.29 
1(4%) 3 (15.7%) 
’ p 2 0.05 vs. DES. MLD: minimal lumen diameter. %DS: % Stenosis diameter. 
Conclusions: DES group presented better acute and late results (larger MLD post, FUP 
and acute gain). Although BT group had a smaller late loss in-stent, angiographic rest- 
enosis and MACE were smaller in the DES group. because of late loss in-segment in this 
group was much smaller. 
ORAL CONTRIBUTIONS 
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10:45 a.m. 
B8OFO-2 Bivalirudin Provides Increasing Benefit With Declining 
Renal Function in Percutaneous Coronary Intervention: 
A Meta-Analysis of 5,035 Patients Enrolled in Three 
Randomized Trials 
Derek P. Chew, Deepak L. Bhatt, Peter B. Berger, Tim Henry, Peter A. McCullough, 
Frederick Feit, John A. Binl, A. Michael Lincoff Flinders Medical Center, Adelaide, 
Australia, The Cleveland Clinic Foundation. Cleveland, OH 
Background: Chronic kidney disease is associated with an increased risk of both 
ischemic and bleeding events during PCI. Bivalirudin reduces both bleeding and 
ischemic complications. We sought to assess the magnitude of benefit in patients strati- 
fied by renal function. 
Methods: We performed a meta-analysis of three randomized trials (BAT, REPLACE-l 
and CACHET) comparing bivalirudin with heparin during PCI in which 5035 pts were 
enrolled. Stratification by renal function was performed by estimated glomerular filtration 
rate (eGFR) as determined by the Cockcroft-Gault equation: >90mls/min (n=l578; 31%]; 
90-80mldmin [n=2163; 43%], 59.30 mls/min (n=l255; 25%], <30ml/min [n=39; I%]. Trial 
specific eGFR strata for death, MI revascularization and hemorrhage were combined 
with a random-effects model. 
Results: lschemlc and bleeding event rates increased with declining eGFR. Across 
strata, the relative benefit of bivalirudin vs. heparin with respect to ischemic events [>90: 
0.79, 90-60:0.73, 59-30: 0.77, ~30: 0.811, and bleeding events [>90: 0.45, 90-60:0.40, 
59-30: 0.461 was maintained. Consequently, the benefit in terms of absolute ischemic 
and bleeding events increased with declining renal function (interactlon p=O.O44). 
Conclusion: Renal dysfunction remains a prevalent risk factor for ischemic and bleeding 
events among patients undergoing PCI. Bivalirudin provides greater absolute benefit in 
reducing these adverse events in patients with impaired renal function. 
DeathlMIIRevasclBleeding 
Bivalirudin Heparin 
Normal 
1 
5.4% 7.6% 
Mild 6.2% 12.0% 
Moderate -_t 9.5% 17.2% 
Severe 9.1% 23.5% 
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1 l:oo a.m. 
88OFO-3 A Prospective, Randomized Placebo-Controlled 
Multicenter Trial Evaluating Fenoldopam Mesylate for 
the Prevention of Contrast Induced Nephropathy: The 
CONTRAST Trial 
Grew W. Stone, Peter McCullough, James Tumlin. Hooman Madyoon. Patrick Murray, 
Andrew Wang, A. Alan Chu. Gary Schaer, Melissa Stevens, Robert L. Wilensky, William 
W. O’Neill, Norman Leper, Cardiovascular Research Foundation and Lenox Hill Heart 
and Vascular Institute, New York, NY 
Background. Contrast-induced nephropathy (CIN) is cmnm~n in pts with basellne 
chronic renal insufficiency undergoing invasive cardiac procedures, and is a powerful 
predictor of early and late morbidity and mortality. Fenoldopam mesylate is a selective 
dopamine-1 agonist that preserves renal medullary blood flow, and has shown promise 
in small studies in preventing CIN. 
We therefore performed a large, multicenter. prospective randomized trial to evaluate 
this agent in pts at risk for CIN. 
Methods.315 pts at 28 U.S. centers with a baseline creatinine clearance (CrCl) of ~60 
cclmin not on dialysis undergoing cardiac catheterization + angioplasty were hydrated 
and randomized 1 :I to I.V.fenoldopam (0.05 uglkglmin titrated up to 0.10 ugikglmin) vs. 
matching placebo, starting 1 hour prior to angiography and continuing for 12 hours there- 
after. Serum creatinine levels were measured at baseline, and at I, 24, 48 and between 
72-98 hours following completion of study drug, and analyzed at a central biochemistry 
lab. The primary endpoint was the incidence of CIN, defined as an increase in serum cre- 
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atinine of >25% from baseline during this 96 hour period. The trial was powered to detect 
a reduction in the primary endpoint from 30% to 15%. Secondary endpoints included 
hospital length of stay, adverse cardiac events, re-hospitalization and need for dialysis 
within 30 days. 
Results. In the pooled population, mean age was 70 + 11 years, 34% were female, 51% 
had diabetes, 67% hypertension, 50% prior MI, and 48% prior CHF. The baseline CrCl 
was 29.2 + 10.1 cc/min (range 7.5-57.5). Mean contrast dose was 164 ?; 155 cc. The 
mean hospital length of stay was 4.0 -+ 5.9 days. Within 30 days, 2.3% required dialysis, 
19.2% were re-hospitalized, and 3.2% of pts died. CIN within 24-96 hours of drug, the pri- 
mary endpoint, occurred in 30.5% of pts. 
Conclusfons. Desvite hvdration and contemoorarv catheterization techniaues. CIN is _ . 
common after invasive cardiac procedures in a population with baseline renal insuff- 
ciencv and oortends a ooor oroonosis. The results of CONTRAST. which examined the 
I  . _  
utility of fenoldopam mesylate. a specific Dl agonist, for the prevention of CIN will be 
unblinded for the first time for presentation in March 2003. 
ll:15a.m. 
88OFO-4 lntracoronary Beta-Blocker Protects the Distal 
Myocardium During Percutaneous Coronary 
Intervention 
Fen Wei Wang, Abdulfatah Osman, Javier Otero, George A. Stouffer, Sergio Waxman, 
Adnan Afzal, Angelo Anzuini, BarN F. Uretsky, The University of Texas Medical Branch, 
Galveston, TX 
Background: Experimental studies have shown that IV beta blockers given before coro- 
nary artery occlusion significantly reduce myocardial injury. We tested the hypothesis 
that intracoronary (C) propranolol(O.015 mgikg) pre-coronary intervention (PCI) reduces 
myocardial necrosis (Ml) and short-term adverse outcomes after PCI. Methods Patients 
(n=150) undergoing elective or urgent PCI were randomly assigned in a prospective dou- 
ble-blind fashion to receive either IC propranolol (n=75) or placebo (n=75). Results 
Major adverse events through the first 30 days are shown in the table and figure. Con- 
clusion: lntracoronary administration of propranolol significantly reduces the incidence 
of Ml after PCI, improves short-term clinical outcomes, and suggests its routine use dur- 
ing PCI. 
30 day Results (% of patients) 
Propranolol (n=75) Placebo (n=75) P value 
Elevated CK-MB 17 36 0.01 
Elevated Troponin T 13 33 0.005 
Death 0 0 NS 
Recurrent Ml 1 3 NS 
Urgent TLR 0 3 NS 
11:30a.m. 
88OFO-5 Marked Survival Benefit Associated With Statin 
Pretreatment Prior to Percutaneous Coronary 
Intervention Is Dependent Upon the Preprocedural 
Inflammatory Status 
Albert W. Ghan Deepak L. Bhan. Derek P. Chew, Joel Reginelli, Deepak P. 
Vivekananthan. Jakob P. Schneider, Eric J. Topol, Stephen G. Ellis, The Ochsner Clinic 
Foundation, New Orleans, LA, The Cleveland Clinic Foundation, Cleveland, OH 
JACC March 19, 2003 
periprocedural myocardial infarction (MI, 5.7% vs 6.1% P=O.O36). At 1 year, statin pre- 
treatment was predictive of survival almost exclusively among patients within the highest 
CRP quartfle (CRP >l.ll mg/dL) (Figure). In multivariate analysis, the interaction 
between CRP quartiles and statin use remained significant (P=O.O14). After adjusting for 
the propensity of receiving statin, statin pretreatment was an independent predictor for l- 
year survival within the highest CRP quartile (H&0.44, P=O.O39). 
Conclusions: Statin therapy prior to PCI is associated with a marked survival benefit 
among patients with high CRP levels, suggesting mechanism tied to a particular anti- 
inflammatory effect. 
11:45 a.m. 
88OFO-6 Prophylactic Acetylcysteine Is Not Effective in 
Preventing Contrast-Induced Nephropathy Following 
Coronary Angiography 
J. Bradlev Oldernever, Erica K. Cichowski, Richard L. Wurdeman, Kathleen A. Packard, 
W. Paul Biddle, Aryan N. Mooss, Creighton University Medical Center, Omaha, NE 
Background: Contrast-Induced Nephropathy (CIN) is associated with significant morbid- 
ity and mortality following coronary angiography. Oral acetylcysteine at a dose of 600 mg 
every twelve hours has had inconsistent results in preventing CIN following contrast 
administration in previously published reports. 
Methods: 96 patients with a creatinine clearance of 50 mllmin or less were randomized 
in a double blinded manner the evening prior to coronary angiography to receive four 
doses of acetylcysteine 1500 mg every twelve hours versus placebo. All patients 
received t/2 normal saline at 1 mlIkg for 12 hours before and 12 hours after angiography. 
CIN was defined as an increase from the baseline serum creatinine (SC) at 46 hours by 
25% or 0.5 mgldl. Multivariate analysis was utilized to identify the incidence of CIN as 
well as the absolute change in SC at 48 hours. 
Results: Baseline characteristics in the groups were similar, with a mean baseline SC of 
1.64 mg/dl. CIN developed in 4 of 49 (6.2%) patients in the acetylcysteine group and 3 of 
47 (6.4%) in the placebo group (p=O.74). Volume of contrast was similar between the two 
groups: 134 ml in the acetylcysteine group and 127 ml in the placebo group (p=O.63). 
The mean change in the SC from baseline and at 46 hours following contrast exposure 
was -0.01 mgldl in the acetylcysteine group and -0.05 mgldl in the placebo group 
(p=O.52). Multiple variables were analyzed with regards to mean change in SC at 48 
hours. The only significant covariate was the volume of contrast dye delivered (p=O.O3). 
There was no benefit of acetylcysteine on change in SC at 46 hours regardless of the 
severity of renal insufficiency. Acetylcysteine was tolerated as well as placebo. 
Conclusion: Acetylcysteine does not appear to prevent CIN in patients with a creatinine 
clearance less than 50 mg/dl who are undergoing coronary angiography. The volume of 
dye delivered continues to be recognized as a potent factor in the deterioration of kidney 
function following angiography. 
Background: Beyond lipid-lowering, statins possess anti-inflammatory and anti-throm- 
botic effects. The relation between statin therapy and lowering of death/Ml early after 
percutaneous coronary intervention (PCI) has been recently shown. We examined the 
inter-relationship of inflammation, statin use. and PCI outcome. 
Methods: Within the year 2000, 1,552 consecutive patients underwent elective/urgent 
PCI at the Cleveland Clinic and were prospectively followed. Pre-procedural serum high- 
sensitivity C-reactive protein (CRP) levels were measured. Comparisons were made 
between patients with and without statin pretreatment. 
Results: Statin-users (39.6%) had a lower median CRP level (0.40 mg/dl vs 0.50 mg/dl, 
P=O.O12) independent of the baseline cholesterol levels, and had less incidence of 
